What is Fulgent Genetics, Inc.'s market cap?

Fulgent Genetics, Inc. (FLGT) has a market capitalization of $556.1M and trades on NASDAQ.

What is Fulgent Genetics, Inc.'s revenue and profitability?

Fulgent Genetics, Inc. generated $320.3M in trailing twelve-month revenue with a net loss of $73.8M, representing a net margin of -23.0%. Gross margin stands at 38.7%, with free cash flow of -$118.2M. These figures are based on the Q1 2026 filing.

Who are Fulgent Genetics, Inc.'s competitors?

Fulgent Genetics, Inc.'s key competitors include GeneDx Holdings Corp., Laboratory Corporation of America Holdings, NeoGenomics, Inc., and others. These companies compete in similar markets and product categories.

Who does Fulgent Genetics, Inc. partner with?

Fulgent Genetics, Inc.'s notable partners include Illumina Inc., Roche Holdings AG, Leica Biosystems, and others.

What subsidiaries does Fulgent Genetics, Inc. have?

Fulgent Genetics, Inc.'s subsidiaries include Fulgent Pharma Holdings, Inc., ANP Technologies, Inc., Fulgent Therapeutics LLC.

Where is Fulgent Genetics, Inc. headquartered?

Fulgent Genetics, Inc. is headquartered in United States of America and employs approximately 1,012 people. It has been publicly traded since 2016.

Fulgent Genetics, Inc.

FLGT

Fulgent Genetics is a technology-driven precision medicine company that operates a large-scale laboratory services business and a therapeutic development division.

Market cap

$556.08M+4.4%

Revenue$320.3M+9.5%

Net income-$73.8M-81.0%

Free cash flow-$118.2M-138%

EPS (diluted)-$2.39-79.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 1, 2026

Revenue$71.1MBeat by $3.0M EPS-$0.36Miss by $0.01

Read the full report

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$94.0M

EPS estimate-$0.46

Financials

Q1 2026

Income statement

See full

Revenue$71.1M-3.2%

Gross profit$21.5M-24.2%

Operating income-$34.6M-74.9%

Net income-$24.8M-115%

EPS (diluted)-$0.80-116%

Balance sheet

See full

Cash & equivalents$23.4M-65.2%

Total debt$8.2M+40.5%

Total equity$1.0B-6.9%

Total assets$1.2B-4.1%

Cash flow

See full

Operating cash flow$7.1M+260%

CapEx$5.2M+10.3%

Free cash flow$1.9M+121%

Valuation & ratios

Valuation

See full

Market cap$556.08M+4.4%

Enterprise value$540.9M+16.0%

P/S1.7×-0.1×

Profitability

See full

Gross margin38.7%-0.1pp

Operating margin-33.1%+17.4pp

Net margin-23%+43.3pp

FCF margin-36.9%—

Returns & leverage

See full

Return on equity-6.8%+48.2pp

Debt / equity0×0.0×

Current ratio5.3×-1.0×

Segments

By segment

See full

Laboratory Services$71.1M-3.3%

Therapeutic Development$87.0K—

By geography

See full

Non Us$6.0M+7.0%

Other Countries$3.5M+14.8%

Competitors

By market cap

Natera, Inc.$37.0B+96.1%

Quest Diagnostics$25.6B+36.3%

Labcorp Holdings$24.7B+13.8%

Tempus AI, Inc.$7.7B-28.0%

GeneDx Holdings$1.8B-25.8%

NeoGenomics$1.7B+106%

Fulgent Genetics, Inc.$556.1M+1.4%

Myriad Genetics$514.7M+27.5%

By revenue growth

Tempus AI, Inc.+69.8%

Natera, Inc.+36.6%

GeneDx Holdings+34.1%

NeoGenomics+11.2%

Quest Diagnostics+9.9%

Fulgent Genetics, Inc.+9.5%

Labcorp Holdings+7.3%

Myriad Genetics-0.3%

By net margin

Quest Diagnostics9.19%+0.2pp

Labcorp Holdings6.66%+1.1pp

NeoGenomics-6.77%+8.3pp

Natera, Inc.-14.61%-3.2pp

GeneDx Holdings-17.58%+1.9pp

Tempus AI, Inc.-22.2%+66.1pp

Fulgent Genetics, Inc.-23.04%-9.1pp

Myriad Genetics-48.24%-36.0pp

Profile

Fulgent Genetics is a technology-driven precision medicine company that operates a large-scale laboratory services business and a therapeutic development division. The company provides a comprehensive menu of genetic and diagnostic tests designed for clinical, biopharmaceutical, and consumer use. Additionally, it leverages a proprietary nanoencapsulation platform to develop targeted drug candidates for the treatment of various cancers.

Competitive position

A technology-focused provider of genetic testing that differentiates through a proprietary software platform and a dual-track strategy of diagnostics and drug development.

GeographiesUnited States, Australia, China, European Union

Customer segmentsHealthcare Providers, Biopharma Research, Governmental Bodies, Individual Consumers

Business modelLaboratory Services, B2B, Direct-to-Consumer, Research and Development

SuppliersNext-generation sequencers, Laboratory reagents, Specialized laboratory equipment, Maintenance and repair services

CustomersPhysicians, Hospitals, Biotech researchers, Health insurance companies, Clinical trial sponsors

CountryUnited States of America

Listed2016

Employees1.0K

CEOMing Hsieh

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitefulgentgenetics.com

FilingsSEC EDGAR

Ask your AI about Fulgent Genetics, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s market cap?: Fulgent Genetics, Inc. (FLGT) has a market capitalization of $556.1M and trades on NASDAQ.
What is Fulgent Genetics, Inc.'s revenue and profitability?: Fulgent Genetics, Inc. generated $320.3M in trailing twelve-month revenue with a net loss of $73.8M, representing a net margin of -23.0%. Gross margin stands at 38.7%, with free cash flow of -$118.2M. These figures are based on the Q1 2026 filing.
Who are Fulgent Genetics, Inc.'s competitors?: Fulgent Genetics, Inc.'s key competitors include GeneDx Holdings Corp., Laboratory Corporation of America Holdings, NeoGenomics, Inc., and others. These companies compete in similar markets and product categories.
Who does Fulgent Genetics, Inc. partner with?: Fulgent Genetics, Inc.'s notable partners include Illumina Inc., Roche Holdings AG, Leica Biosystems, and others.
What subsidiaries does Fulgent Genetics, Inc. have?: Fulgent Genetics, Inc.'s subsidiaries include Fulgent Pharma Holdings, Inc., ANP Technologies, Inc., Fulgent Therapeutics LLC.
Where is Fulgent Genetics, Inc. headquartered?: Fulgent Genetics, Inc. is headquartered in United States of America and employs approximately 1,012 people. It has been publicly traded since 2016.